Terug
65
34
46
24
Ook genoteerd als
GNMSF
OTC
Dagbereik
€ 25,43
€ 25,86
52-Weeksbereik
€ 17,24
€ 35,43
Volume
1.562.050
50D / 200D Gem.
€ 30,31
/
€ 27,96
Vorige Slotkoers
€ 25,68
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 2,6 | 0,3 |
| P/B | 0,4 | 2,9 |
| ROE % | 16,6 | 3,7 |
| Net Margin % | 25,9 | 3,8 |
| Rev Growth 5Y % | 29,6 | 10,0 |
| D/E | 1,0 | 0,2 |
Koersdoel Analisten
Hold
€ 40,50
+56.9%
Low: € 34,00
High: € 48,00
Forward K/W
20,8
Forward WPA
€ 1,24
WPA Groei (sch.)
+0,0%
Omzet Sch.
4,3 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 2,68
€ 2,46 – € 2,88
|
6,5 B | 4 |
| FY2029 |
€ 2,42
€ 2,22 – € 2,60
|
6,2 B | 4 |
| FY2028 |
€ 2,61
€ 1,81 – € 3,39
|
6,1 B | 10 |
Belangrijkste Punten
Revenue grew 29,58% annually over 5 years — strong growth
Earnings declined -21,69% over the past year
ROE of 16,63% — decent returns on equity
Net margin of 25,89% shows strong profitability
Generating 7,33B in free cash flow
P/E of 2,59 — trading at a low valuation
Groei
Revenue Growth (5Y)
29,58%
Revenue (1Y)10,23%
Earnings (1Y)-21,69%
FCF Growth (3Y)2,29%
Kwaliteit
Return on Equity
16,63%
ROIC8,24%
Net Margin25,89%
Op. Margin33,60%
Veiligheid
Debt / Equity
0,95
Current Ratio2,02
Interest Coverage20,49
Waardering
P/E Ratio
2,59
P/B Ratio0,43
EV/EBITDA5,07
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,23% | Revenue Growth (3Y) | 20,01% |
| Earnings Growth (1Y) | -21,69% | Earnings Growth (3Y) | 18,80% |
| Revenue Growth (5Y) | 29,58% | Earnings Growth (5Y) | 20,05% |
| Profitability | |||
| Revenue (TTM) | 23,73B | Net Income (TTM) | 6,14B |
| ROE | 16,63% | ROA | 7,50% |
| Gross Margin | 91,69% | Operating Margin | 33,60% |
| Net Margin | 25,89% | Free Cash Flow (TTM) | 7,33B |
| ROIC | 8,24% | FCF Growth (3Y) | 2,29% |
| Safety | |||
| Debt / Equity | 0,95 | Current Ratio | 2,02 |
| Interest Coverage | 20,49 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 2,59 | P/B Ratio | 0,43 |
| P/S Ratio | 0,67 | PEG Ratio | -1,06 |
| EV/EBITDA | 5,07 | Dividend Yield | 0,00% |
| Market Cap | 15,94B | Enterprise Value | 40,39B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 23,73B | 21,53B | 16,47B | 14,51B | 8,42B |
| Net Income | 6,14B | 7,84B | 4,35B | 5,45B | 2,96B |
| EPS (Diluted) | 9,79 | 12,14 | 6,60 | 8,26 | 4,48 |
| Gross Profit | 21,76B | 20,54B | 16,25B | 14,51B | 8,42B |
| Operating Income | 7,97B | 6,70B | 5,32B | 6,27B | 2,95B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 81,86B | 45,81B | 35,29B | 30,12B | 24,63B |
| Total Liabilities | 44,68B | 9,11B | 3,68B | 2,84B | 2,43B |
| Shareholders' Equity | 37,18B | 36,70B | 31,61B | 27,28B | 22,20B |
| Total Debt | 35,36B | 1,03B | 770,00M | 597,00M | 425,00M |
| Cash & Equivalents | 10,91B | 9,86B | 14,87B | 9,89B | 8,96B |
| Current Assets | 18,35B | 27,85B | 33,14B | 28,22B | 22,74B |
| Current Liabilities | 9,07B | 5,31B | 2,48B | 1,82B | 1,57B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#160 of 1052
Custom
Capital Light Compounder
#139 of 218
#213 of 618
#388 of 670
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Capital Light Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026